3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Polycystic Ovary Syndrome
8
Hyperandrogenism
4
Neoplasms
3
Inflammation
2
Heart Failure
2
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Sarcoma
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Obesity
1
Neutropenia
1
Migraine Disorders
1
Metabolic Syndrome
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Lymphoma
1
Intraabdominal Infections
1
Influenza, Human
1
Infections
1
Interventions
Echocardiography
14
Doxorubicin
10
Exercise
8
Electrocardiography
7
Trastuzumab
6
Cyclophosphamide
5
Carvedilol
5
Docetaxel
3
Atorvastatin
3
salicylhydroxamic acid
2
sacubitril and valsartan sodium hydrate drug combination
2
empagliflozin
2
dapagliflozin
2
Tablets
2
Social Determinants of Health
2
Silymarin
2
Magnetic Resonance Spectroscopy
2
Ivabradine
2
High-Intensity Interval Training
2
Exercise Test
2
Chemoradiotherapy
2
Blood Specimen Collection
2
Bisoprolol
2
Antineoplastic Agents
2
Anthracyclines
2
sulforaphane
1
schizandrin
1
pegfilgrastim
1
nicotinamide-beta-riboside
1
mitoquinone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cardiotoxicity
×
Spironolactone
×
Clear all
NCT06005259
2023-08-22
SPIROTOX
University of Sao Paulo
Phase 4
Unknown
264 enrolled